Diabetic neuropathy: an evaluation of the use of quercetin in the cecum of rats

World J Gastroenterol. 2013 Oct 14;19(38):6416-26. doi: 10.3748/wjg.v19.i38.6416.

Abstract

Aim: To investigate the effect of quercetin supplementation on the myenteric neurons and glia in the cecum of diabetic rats.

Methods: Total preparations of the muscular tunic were prepared from the ceca of twenty-four rats divided into the following groups: control (C), control supplemented with quercetin (200 mg/kg quercetin body weight) (CQ), diabetic (D) and diabetic supplemented with quercetin (DQ). Immunohistochemical double staining technique was performed with HuC/D (general population)/nitric oxide synthase (nNOS), HuC-D/S-100 and VIP. Density analysis of the general neuronal population HuC/D-IR, the nNOS-IR (nitrergic subpopulation) and the enteric glial cells (S-100) was performed, and the morphometry and the reduction in varicosity population (VIP-IR) in these populations were analyzed.

Results: Diabetes promoted a significant reduction (25%) in the neuronal density of the HuC/D-IR (general population) and the nNOS-IR (nitrergic subpopulation) compared with the C group. Diabetes also significantly increased the areas of neurons, glial cells and VIP-IR varicosities. Supplementation with quercetin in the DQ group prevented neuronal loss in the general population and increased its area (P < 0.001) and the area of nitrergic subpopulation (P < 0.001), when compared to C group. Quercetin induced a VIP-IR and glial cells areas (P < 0.001) in DQ group when compared to C, CQ and D groups.

Conclusion: In diabetes, quercetin exhibited a neuroprotective effect by maintaining the density of the general neuronal population but did not affect the density of the nNOS subpopulation.

Keywords: Diabetes; Enteric glia; Myenteric plexus; Neuronal nitric oxide synthase; Neuroprotection; Vasoactive intestinal polypeptide.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cecum / innervation*
  • Diabetes Mellitus, Experimental / complications
  • Diabetic Nephropathies / drug therapy*
  • Diabetic Nephropathies / etiology
  • Diabetic Nephropathies / metabolism
  • Diabetic Nephropathies / pathology
  • Diabetic Nephropathies / physiopathology
  • ELAV Proteins / metabolism
  • ELAV-Like Protein 3
  • ELAV-Like Protein 4
  • Male
  • Myenteric Plexus / drug effects*
  • Myenteric Plexus / metabolism
  • Myenteric Plexus / pathology
  • Myenteric Plexus / physiopathology
  • Neuroglia / drug effects
  • Neuroglia / metabolism
  • Neurons / drug effects
  • Neurons / metabolism
  • Neuroprotective Agents / pharmacology*
  • Nitrergic Neurons / drug effects
  • Nitrergic Neurons / metabolism
  • Nitric Oxide Synthase Type I / metabolism
  • Quercetin / pharmacology*
  • Rats
  • Rats, Wistar
  • S100 Proteins / metabolism
  • Vasoactive Intestinal Peptide / metabolism

Substances

  • ELAV Proteins
  • ELAV-Like Protein 3
  • ELAV-Like Protein 4
  • Elavl3 protein, rat
  • Elavl4 protein, rat
  • Neuroprotective Agents
  • S100 Proteins
  • Vasoactive Intestinal Peptide
  • Quercetin
  • Nitric Oxide Synthase Type I
  • Nos1 protein, rat